Key Takeaways:
Replimune Group presented 3-year landmark overall survival data from its IGNYTE clinical trial of RP1 plus nivolumab in patients with anti-PD-1 failed melanoma during an oral session at the American Society of Clinical Oncology annual meeting on May 30.
"These data demonstrate the potential of RP1 to provide durable survival benefit in a patient population with limited treatment options," the company said in its presentation at ASCO 2026 in Chicago.
The IGNYTE trial evaluates RP1, an oncolytic immunotherapy derived from herpes simplex virus, combined with Bristol Myers Squibb's nivolumab, a PD-1 checkpoint inhibitor. The study targets patients whose melanoma progressed after anti-PD-1 therapy, a group with historically poor outcomes and few approved options beyond chemotherapy or clinical trials. Replimune's approach uses RP1 to infect and lyse tumor cells, triggering an immune response that, when combined with nivolumab's checkpoint blockade, may overcome resistance to prior immunotherapy.
The 3-year landmark analysis provides the longest follow-up data to date for this combination in the post-anti-PD-1 melanoma setting. Replimune did not disclose the specific survival rate, hazard ratio, or patient count in the summary release. The company has not provided a timeline for a potential Biologics License Application filing.
For investors, the ASCO presentation represents a key catalyst for REPL shares. The stock has historically moved on clinical data readouts, and positive survival data in a high-need melanoma population could support the company's regulatory path. Replimune, which trades on the Nasdaq, has not yet disclosed its current cash position or runway.
This article is for informational purposes only and does not constitute investment advice.
